Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Quest Diagnostics

Share:
Related DGX
18 Biggest Mid-Day Gainers For Monday
Benzinga's Top Upgrades
The Most And Least Loved Stocks In The S&P 500 (Seeking Alpha)

In a report published Monday, Jefferies & Company reiterated its Hold rating on Quest Diagnostics (NYSE: DGX), but lowered its price target from $63.00 to $59.00.

Jefferies noted, “We continue to have a neutral view on DGX given our belief that ongoing weakness in lab volumes will persist and keep the stock rangebound near-term. While we are optimistic that mgmt's efforts to restructure operations and rationalize expenses will achieve their targets, we recognize that this process, which could be the key catalyst for the stock, will take time to complete.”

Quest Diagnostics closed on Friday at $57.94.

Latest Ratings for DGX

DateFirmActionFromTo
Nov 2016UBSUpgradesNeutralBuy
Sep 2016CitigroupInitiates Coverage onNeutral
Aug 2016MizuhoDowngradesBuyNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!